Charles L. Sawyers
Born
Charles Lazelle Sawyers[1]

1959 (age 64–65)
Nashville, Tennessee
EducationJohns Hopkins University, Princeton, UCSF
Medical career
ProfessionPhysician
InstitutionsMemorial Sloan Kettering Cancer Center
Howard Hughes Medical Institute
Sub-specialtiesOncologist
ResearchLeukemia/prostate cancer
AwardsLasker Clinical Award (2009)
BBVA Foundation Frontiers of Knowledge Award (2014)
WebsiteThe Charles Sawyers Lab

Charles L. Sawyers (born 1959) is a Howard Hughes Medical Institute (HHMI) investigator who holds the Marie-Josée and Henry R. Kravis Chair of the Human Oncology and Pathogenesis Program (HOPP) at Memorial Sloan Kettering Cancer Center (MSK). HOPP is a program created in 2006 that comprises researchers from many disciplines to bridge clinical and laboratory discoveries.[2]

Career

Sawyers received a BA from Princeton University in 1981 and an MD from Johns Hopkins University School of Medicine in 1985,[3] followed by an internal medicine residency at the University of California, San Francisco.[4] He became a HHMI investigator in 2002 while working at UCLA's Jonsson Cancer Center.[5]

Sawyers works on molecularly targeted cancer drugs, with a focus on developing a new generation of treatment options for patients. He shared the 2009 Lasker-DeBakey Clinical Medical Research Award with Brian J. Druker and Nicholas Lydon,[6] for the development of the ABL kinase inhibitor imatinib for patients with chronic myeloid leukemia and the second-generation ABL inhibitor dasatinib to overcome imatinib resistance. He also co-discovered the antiandrogen drugs enzalutamide, approved by the FDA in 2012, and apalutamide[7] approved in 2019, both for treatment of advanced prostate cancer.[8]

Sawyers' cancer research is discussed in the second episode of Cancer: The Emperor of All Maladies.

Significant positions

Sawyers served as president of the American Society for Clinical Investigation (ASCI) in 2007[9] and of the American Association for Cancer Research (AACR) in 2012.[10] He was also appointed to the National Cancer Advisory Board by President Obama in 2012,[11] and has served on the Board of Directors of Novartis since 2013.[12] He was a founding co-editor of the Annual Review of Cancer Biology in 2017,[13] serving until 2021.[14]

Memberships

Awards

References

  1. ↑ Howard Hughes Medical Institute, Annual Scientific Report, The Institute, 1990, p. 507.
  2. ↑ "At Work: Human Oncology and Pathogenesis Program Chair Charles Sawyers | Memorial Sloan Kettering Cancer Center". www.mskcc.org. Retrieved 5 April 2017.
  3. ↑ "Susan Schneck Weds Charles Sawyers". The New York Times. 22 October 1990. Retrieved 3 March 2017.
  4. ↑ "UCSF Department of Medicine Alumni Profile: Dr. Charles Sawyers". medicine.ucsf.edu. Archived from the original on 8 September 2015. Retrieved 3 March 2017.
  5. ↑ "Charles L. Sawyers, MD". HHMI.org. Retrieved 5 April 2017.
  6. ↑ Grindlinger, Brooke; Chao, ES (1 October 2009). "Trio receives Lasker Foundation Clinical Award for breakthroughs in leukemia treatment". Journal of Clinical Investigation. 119 (10): 2863–2865. doi:10.1172/JCI41141. ISSN 0021-9738. PMC 2752112.
  7. ↑ Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, Wongvipat J, Smith-Jones PM, Yoo D, Kwon A, Wasielewska T, Welsbie D, Chen CD, Higano CS, Beer TM, Hung DT, Scher HI, Jung ME, Sawyers CL (2009). "Development of a second-generation antiandrogen for treatment of advanced prostate cancer". Science. 324 (5928): 787–90. Bibcode:2009Sci...324..787T. doi:10.1126/science.1168175. PMC 2981508. PMID 19359544.
  8. ↑ Reyes, Antonio A.; Akeson, Richard (1988). "Generation of Multiple Independent Substitution Mutants by M13 in Vitro Mutagenesis Using a Single Mutagenic Oligonucleotide". DNA. 7 (8): 579–584. doi:10.1089/dna.1.1988.7.579. PMID 3180999.
  9. ↑ "2008 American Society of Clinical Investigation Presidential Address" (PDF). the-asci.org. Retrieved 3 March 2017.
  10. ↑ "Charles L. Sawyers, MD". aacr.org. Retrieved 4 March 2017.
  11. ↑ "President Obama Announces More Key Administration Posts". whitehouse.gov. 6 December 2012. Retrieved 4 March 2017.
  12. ↑ "Charles L. Sawyers, M.D. Member of the Board of Directors" (PDF). novartis.com. Retrieved 4 March 2017.
  13. ↑ Jacks, Tyler; Sawyers, Charles (2017). "Introduction". Annual Review of Cancer Biology. 1: i. doi:10.1146/annurev-ca-01-121516-100001.
  14. ↑ "Annual Review of Cancer Biology Editorial Committee". Annual Reviews. 2022. Retrieved 18 July 2022.
  15. ↑ "Doris Duke Charitable Foundation Awards $10.5 Million for Medical Research". Philanthropy News Digest (PND). Retrieved 5 April 2017.
  16. ↑ "Recipients of the David A. Karnofsky Memorial Award and Lecture - The ASCO Post". www.ascopost.com. Archived from the original on 19 September 2017. Retrieved 5 April 2017.
  17. ↑ "Awards, Appointments, Announcements". JNCI Journal of the National Cancer Institute. 97 (11): 797. 1 June 2005. doi:10.1093/jnci/97.11.797.
  18. ↑ "Dorothy P. Landon-AACR Prize for Translational Cancer Research". www.aacr.org. Archived from the original on 3 September 2017. Retrieved 5 April 2017.
  19. ↑ Foundation, Lasker. "Molecularly targeted treatments for chronic myeloid leukemia | The Lasker Foundation". The Lasker Foundation. Retrieved 5 April 2017.
  20. ↑ "Breakthrough Prize". breakthroughprize.org. Retrieved 5 April 2017.
  21. ↑ "Taubman Prize". A. Alfred Taubman Medical Research Institute. Retrieved 16 March 2017.
  22. ↑ "2014 Honorees". The Hope Funds for Cancer Research. 5 September 2013. Retrieved 5 April 2017.
  23. ↑ "BBVA Foundation Frontiers of Knowledge Awards". www.fbbva.es. Archived from the original on 21 September 2015. Retrieved 5 April 2017.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.